# Single Oral Doses Study of Nerispirdine on Visual Function in Patients With Multiple Sclerosis

> **NCT00772525** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 31 (actual)

## Conditions studied

- Multiple Sclerosis
- Optic Nerve
- Neuritis

## Interventions

- **DRUG:** Nerispirdine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00772525
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2016-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00772525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00772525, "Single Oral Doses Study of Nerispirdine on Visual Function in Patients With Multiple Sclerosis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00772525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*